Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
about
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.Recent developments in the treatment of metastatic colorectal cancer.Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR.Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer.Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study.Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles.Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.TAS-102 and the quest for predictive biomarkers.
P2860
Q38764838-24A49859-03E7-43E9-A2F1-249565EB3FEAQ39438832-FE89EE8F-D664-4AA9-8048-64A42B14DB9EQ40040773-85613A87-DC0C-4FC6-801B-91513AE887F6Q40226443-BA222A3A-AB09-432B-8AAA-E80C8AE7D0CCQ41105389-7E2261B5-4988-4DE2-A1C5-B0B9D8401CE6Q47095094-232DCEA0-4E94-42BF-8632-5DD1A29E27B7Q49679318-95D21756-6640-4309-AC52-84CF385B2848Q50201433-DF4593A5-ACE2-4E43-BF3E-B828BC17B65EQ52657104-61B1D3A8-F6FE-4F4A-BC4B-11C56B257F46Q54949200-02176D64-3DA1-4A0F-B19F-8900A331CB73Q55003977-80936B0C-79FE-45E2-B0A4-BD2103826050Q55154129-CE66CEBA-9C65-41D7-9C18-E3A672573BE4Q55280505-4A51BE5E-9AD5-4C59-A7C9-B6BFB2ABF1D7Q55358017-2B30C2FC-A318-4E0F-AA27-947414FB45ECQ55389129-B4636037-1F6A-4FD0-A67F-BB1E8D8B1F33
P2860
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@ast
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@en
type
label
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@ast
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@en
prefLabel
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@ast
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@en
P2093
P2860
P356
P1433
P1476
Outcome according to KRAS-, NR ...... colorectal cancer study group.
@en
P2093
A Reinacher-Schick
A Tannapfel
C Giessen-Jung
D P Modest
H J Schmoll
L F von Weikersthal
R Porschen
P2860
P304
P356
10.1093/ANNONC/MDW261
P50
P577
2016-06-29T00:00:00Z